Jorge Duconge to Puerto Rico
This is a "connection" page, showing publications Jorge Duconge has written about Puerto Rico.
Connection Strength
0.700
-
Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nu?ez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int J Environ Res Public Health. 2018 05 30; 15(6).
Score: 0.113
-
Hernandez-Suarez DF, Scott SA, Tomey MI, Melin K, Lopez-Candales A, Buckley CE, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis. 2017 Sep; 11(9):235-241.
Score: 0.106
-
Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, Garc?a R, Hern?ndez G, Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metab Pers Ther. 2015 Dec; 30(4):239-49.
Score: 0.095
-
Valent?n II, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, Rua?o G, Duconge J. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J. 2014 Sep; 33(3):97-104.
Score: 0.087
-
Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Rua?o G, Duconge J. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother. 2012 Feb; 46(2):208-18.
Score: 0.073
-
Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Rua?o G. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis. 2009; 19(4):390-5.
Score: 0.059
-
Duconge J, Cadilla CL, Renta JY, Sil?n-Rivera P, Piovanetti P, Garc?a-Berdec?a R, Castro-Rosario LM, Monz?n S, V?lez L, Rosas G, Guerra JA, Santiago-Borrero PJ. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. P R Health Sci J. 2008 Dec; 27(4):357-8.
Score: 0.058
-
Morales P, Santiago L, Rosario J, Garcia-Fragoso L, Duconge J, Perez N, Santiago D. Neonatal Abstinence Syndrome and Corresponding Pharmacotherapy Approaches from 2 University-affiliated Neonatal Intensive Care Units in Puerto Rico (2018-2020). P R Health Sci J. 2024 Mar; 43(1):25-31.
Score: 0.042
-
Santiago D, Rosario Y, Melin K, Duconge J, Roman L, Gonzalez A, Venkataramanan R. Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study. P R Health Sci J. 2021 12; 40(4):192-194.
Score: 0.036
-
Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Rua?o G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 06; 411(17-18):1306-11.
Score: 0.016
-
Rua?o G, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Villagra D, Renta J, Holford T, Santiago-Borrero PJ. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics. 2009 Apr; 10(4):565-77.
Score: 0.015